PureTech Health welcomes Sharon Barber-Lui to its Board as Non-Executive Director

– USA, MA – PureTech Health plc (Nasdaq: PRTC | LON: PRTC), a clinical-stage biotherapeutics company today announced the appointment of Sharon Barber-Lui to its board as a non-executive director.

“Sharon has a track record of success and leadership spanning diverse experiences across the life sciences industry, with particular expertise in financial systems and governance. We are very pleased to have her join PureTech’s board. On behalf of the board, I welcome Sharon and look forward to her contributions,” said Board Chair, Chris Viehbacher.

Sharon Barber-Lui will also join the Audit Committee as chair-designate

About Sharon Barber-Lui

Sharon Barber-Lui previously led U.S. Oncology Portfolio Market Strategy, Operations, and Business Analytics at Merck & Co. Inc. During her two decades at Merck & Co. Inc., Ms. Barber-Lui has held multiple financial and operational positions of increasing responsibility, including CFO of U.S. Oncology, Director of U.S. Treasury Operations and regional Treasurer of Asia Pacific. She currently serves as the SVP of Global Finance at EQRx. Ms. Barber-Lui brings extensive experience in finance, operations, portfolio management, and commercialization to PureTech’s board of industry, business, and academic leaders.

“I am energized by PureTech’s unique model and approach to creating new therapies for devastating diseases. PureTech is a true pioneer, and I look forward to joining the distinguished members of the board to help support PureTech’s talented team in executing on the collective vision of transforming patient care by giving life to science,” said Ms. Barber-Lui.

Ms. Barber-Lui has more than 20 years of diverse experiences at Fortune 50 and major public accountancies with a strong life science innovation, entrepreneurship, and business transformation activity. Since 2022, she has served as SVP of Global Finance at EQRx, a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices. She also led Portfolio Market Strategy, Operations, and Business Analytics at Merck & Co. Inc.’s U.S. Oncology business from 2019 through 2021, where she previously served as CFO of U.S. Oncology from 2014 to 2018. That business portfolio included new, mature, co-developed, and co-commercialized products. Ms. Barber-Lui also held several other financial and operational related roles throughout her 22 years at Merck & Co. Inc. Ms. Barber-Lui received her MBA, marketing and corporate entrepreneurship, and her B.S. in accounting from Lehigh University.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing, and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases, and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders. This pipeline, which is being advanced both internally and through PureTech’s Founded Entities, is comprised of 25 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech’s most recently filed Half Year Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company’s unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems referred to as the BIG Axis.

For more information: https://puretechhealth.com/